Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Nrf2 activator

Omaveloxolone

Brand names: Skyclarys

Omaveloxolone is an oral agent used in the treatment of Friedreich's ataxia, a progressive inherited neurodegenerative disorder.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It activates the Nrf2 transcription factor, upregulating antioxidant and mitochondrial defence pathways to counter the oxidative stress and mitochondrial dysfunction characteristic of Friedreich's ataxia.

Prescribing in practice

  • Monitor liver function, as elevations in transaminases can occur, and check before and periodically during treatment as advised in the SPC.
  • Lipid parameters and B-type natriuretic peptide may change, so review these during treatment.
  • Several medicines interact via cytochrome P450 pathways, so review concomitant therapy against current prescribing references.

Monitoring

Monitor liver function tests, lipids and weight periodically during treatment.

Counselling the patient

  • Take consistently with respect to food as directed and do not take with a high-fat meal unless advised.
  • Attend for blood tests to check your liver during treatment.
  • Tell your clinician about all other medicines, as interactions are possible.

Evidence & guidelines

Omaveloxolone is approved for Friedreich's ataxia on the basis of a randomised trial showing improvement in neurological function as measured by a standard ataxia rating scale.

Reference: NICE; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Pathways